Screener
G&A at other companies
Other financials
Where this comes from
Reported directly by AngioDynamics in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: AngioDynamics’s 10-K, filed July 14, 2026.
- Filed
- Jul 14, 2026, 3:42 PM EDT
- Fiscal year
- FY2026
- Accession
- 0001628280-26-048138
| Line item | Year ended May 31, 2026 | Year ended May 31, 2025 | Year ended May 31, 2024 |
|---|---|---|---|
| Operating expenses | |||
| Research and development | 29,447 | 26,222 | 31,512 |
| Sales and marketing | 113,401 | 103,135 | 102,818 |
| General and administrative | 43,691 | 42,092 | 41,164 |
| Amortization of intangibles | 10,682 | 10,318 | 13,048 |
| Goodwill impairment | — | — | 159,476 |
| Change in fair value of contingent consideration | — | 272 | 432 |
| Acquisition, restructuring and other items, net | 17,598 | 15,620 | 53,182 |
Item 15. Exhibits, Financial Statement Schedules.
FAQ
- What is AngioDynamics's G&A?
- AngioDynamics (ANGO) reported G&A of $10.27M in Q1 2026.
- How has AngioDynamics's G&A changed year-over-year?
- AngioDynamics's G&A increased by 0.3% year-over-year, from $10.24M to $10.27M.
- What is the long-term trend for AngioDynamics's G&A?
- Over 4 years (2022 to 2026), AngioDynamics's G&A has grown at a 3.2% compound annual growth rate (CAGR), from $38.45M to $43.69M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about AngioDynamics's g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude